Acquisition Momentum LabConnect acquired A4P Bio in April 2024, signaling a consolidation of preclinical and clinical trial support services and potential cross-sell opportunities across their combined client base.

Integrated Services A4P offers end-to-end support from biomarker strategy and consultancy to clinical biosample operations and logistics, presenting opportunities to upsell integrated lab analytics, sourcing, and global sample management to pharma and biotech customers.

Clinical Focus With expertise spanning preclinical to submission, there is a strong sales case for expanding collaborations on biomarker-driven trials, companion diagnostics, and data generation services aligned with regulatory submissions.

Scale and Reach Post-acquisition, LabConnect and A4P together can target larger CROs and pharmaceutical companies seeking scalable central laboratory and FSP solutions, leveraging global logistics and diverse therapeutic experience.

Tech and Operations A4P’s logistics and biosample management capability complements digital platforms and data workflows; a joint offering can emphasize streamlined, compliant, end-to-end trial operations to win complex, multicenter studies.